See more : The PNC Financial Services Group, Inc. (PNC) Income Statement Analysis – Financial Results
Complete financial analysis of Valeo Pharma Inc. (VPHIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valeo Pharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- TAV Havalimanlari Holding A.S. (TAVHY) Income Statement Analysis – Financial Results
- HWASHIN CO.,Ltd (010690.KS) Income Statement Analysis – Financial Results
- Masco Corporation (MAS) Income Statement Analysis – Financial Results
- Global One Real Estate Investment Corp. (8958.T) Income Statement Analysis – Financial Results
- Huvis Corporation (079980.KS) Income Statement Analysis – Financial Results
Valeo Pharma Inc. (VPHIF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.valeopharma.com
About Valeo Pharma Inc.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 53.91M | 27.75M | 13.56M | 7.47M | 6.58M | 4.38M | 1.28M | 985.71K |
| Cost of Revenue | 40.83M | 21.46M | 9.60M | 6.09M | 5.18M | 3.55M | 747.09K | 2.35M |
| Gross Profit | 13.08M | 6.28M | 3.96M | 1.38M | 1.40M | 832.97K | 530.40K | -1.37M |
| Gross Profit Ratio | 24.26% | 22.64% | 29.17% | 18.49% | 21.30% | 19.01% | 41.52% | -138.68% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 126.26K | 0.00 |
| General & Administrative | 22.56M | 18.81M | 13.31M | 3.32M | 3.04M | 2.98M | 2.84M | 1.10M |
| Selling & Marketing | 6.59M | 6.09M | 2.89M | 2.12M | 2.01M | 236.53K | 133.75K | 72.75K |
| SG&A | 29.15M | 24.90M | 16.19M | 5.45M | 5.05M | 3.22M | 2.98M | 1.01M |
| Other Expenses | 1.15M | 0.00 | 123.00K | 198.00K | 253.00K | 147.04K | 50.77K | 0.00 |
| Operating Expenses | 30.31M | 25.39M | 16.65M | 5.68M | 5.14M | 3.26M | 3.14M | 1.01M |
| Cost & Expenses | 71.14M | 46.86M | 26.25M | 11.77M | 10.31M | 6.81M | 3.89M | 3.36M |
| Interest Income | 3.72M | 173.00K | 1.00K | 1.00K | 0.00 | 816.00 | 368.00 | 114.17K |
| Interest Expense | 13.79M | 6.46M | 1.36M | 598.00K | 110.00K | 173.85K | 102.42K | 0.00 |
| Depreciation & Amortization | 2.63M | 1.42M | 743.00K | 424.00K | 135.00K | 44.47K | 40.12K | 38.56K |
| EBITDA | -11.39M | -17.56M | -11.86M | -3.74M | -3.41M | -2.33M | -2.55M | -2.34M |
| EBITDA Ratio | -21.13% | -63.28% | -87.47% | -49.44% | -51.85% | -53.13% | -199.81% | -237.24% |
| Operating Income | -17.23M | -19.60M | -12.94M | -4.12M | -3.55M | -2.37M | -2.59M | -2.38M |
| Operating Income Ratio | -31.96% | -70.66% | -95.45% | -55.11% | -53.90% | -54.15% | -202.95% | -241.15% |
| Total Other Income/Expenses | -10.58M | -7.32M | -1.42M | -644.00K | 122.00K | 28.00K | -1.86M | 460.53K |
| Income Before Tax | -27.81M | -26.92M | -14.23M | -4.76M | -3.62M | -2.40M | -4.50M | -1.92M |
| Income Before Tax Ratio | -51.58% | -97.03% | -104.99% | -63.73% | -54.96% | -54.78% | -352.25% | -194.43% |
| Income Tax Expense | 0.00 | -1.17M | 1.48M | 796.00K | 326.00K | 36.72K | -881.21K | -640.00K |
| Net Income | -27.81M | -25.75M | -14.23M | -4.76M | -3.62M | -2.44M | -3.62M | -1.28M |
| Net Income Ratio | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% | -55.62% | -283.27% | -129.50% |
| EPS | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| EPS Diluted | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| Weighted Avg Shares Out | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
| Weighted Avg Shares Out (Dil) | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
Valeo Pharma projects record revenues and margins for its second quarter following Redesca launch
Valeo Pharma Projecting Record Revenues for Second Quarter 2021
Valeo Pharma joins the Innovative Medicines Canada Association
Valeo Pharma making progress as it bids to become leading Canada-focused specialty pharma group
Valeo Pharma signs agreement for the listing of Redesca and Redesca HP on the Ontario Drug Benefit Formulary with effect from April 30
Valeo Pharma upsizes and closes a $6.645 million non-brokered private placement of unsecured non-convertible debenture units
Valeo Pharma Inc. upsizes and closes a $6.645 million non-brokered private placement of unsecured non-convertible debenture units
Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement
Valeo Pharma commences commercial shipments of Redesca and Redesca HP across Canada
Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™
Source: https://incomestatements.info
Category: Stock Reports